Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 149 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 Emma Stone Motivated to Help Others After Her Mother Was Diagnosed... November 16, 2020 Patient Guide in Hepatocellular Carcinoma Now Available Also in German December 16, 2025 FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer November 8, 2023 Load more HOT NEWS Qué saber al buscar información sobre el cáncer en línea: perspectiva... Cannabis, cannabinoids and cancer – the evidence so far Beating the Heat with Beets Latest episode of our podcast for researchers
